Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization

Cytotherapy

Volumn 14, Issue 7, 2012, Pages 823-829

  Sancho, Juan Manuel ^a   Morgades, Mireia ^a   Grifols, Joan Ramon ^b   Juncà, Jordi ^a   Guardia, Ramon ^c   Vives, Susana ^a   Ferrà, Christelle ^a   Batlle, Monsterrat ^a   Ester, Anna ^b   Gallardo, David ^c   Millà, Fuensanta ^a   Feliu, Evarist ^a   Ribera, Josep Maria ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Banc de Sang i Teixits   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Lymphoma; Mobilization; Multiple myeloma; Plerixafor; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34+ CELL COUNT; CHILD; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL MOBILIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84863951668     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.681042     Document Type: Article

References (40)

1. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997; 89:2233-58.
2. +peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 2004;13:598-606.
3. Vose JM, Ho AD, Coiffi er B, Corradini P, Khouri I, Sureda A, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009; 50:1412-21.
4. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral-Blood progenitor cells mobilised by fi lgrastim (G-CSF) on platelet recovery after high-Dose chemotherapy. Lancet. 1992;339:640-4.
5. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992;9:277-84.
6. Reiffers J, Faberes C, Boiron JM, Marit G, Foures C, Ferrer AM, et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: Analysis of factors affecting the rate of engraftment. J Hematother. 1994;3:185-91.
7. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961-9.
8. + cells or unmanipulated peripheral blood stem and progenitors cells. Transfusion. 1998;38:199-208.
9. +cells ( ' super mobilizers ' ) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007;40:437-41.
10. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118: 4530-40.
11. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving suffi cient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045-56.
12. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells. Definitions, incidence, risk factors and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490-9.
13. Sancho JM, Ribera JM, Oriol A, Batlle M, Flores A, Rodríguez Ll, et al. Causas por las que no se realiza el trasplante de progenitores hematopoy é ticos en pacientes remitidos a una unidad de trasplante. Med Clin (Barc). 2003;121:401-4.
14. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83: 3787-94.
15. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113: 5720-6.
16. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. 3101 Investigators. Phase III prospective randomized double-Blind placebo-Controlled trial of plerixafor plus granulocyte colony-Stimulating factor compared with placebo plus granulocyte colony-Stimulating factor for autologous stem-Cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767-73.
17. Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol. 2011; 86:488-95.
18. Hü bel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin ' s lymphoma, Hodgkin ' s lymphoma and multiple myeloma patients. A subgroup ana lysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2011. doi:10.1038/bmt. 2011.216.
19. Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant. 2011. doi:10.1038/bmt. 2011.217.
20. Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J. A risk-Based approach to optimize autologous hematopoietic stem cell (HSC) collection with use of plerixafor. Bone Marrow Transplant. 2012;47:483-487.
21. Jantunen E, Lemoli RM. Preemptive use of plerixafor in diffi cult-To-Mobilize patients: An emerging concept. Transfusion. 2012;52:906-914.
22. + cell determination by flow cytometry. Hematotherapy J. 1996;5:213-26.
23. + cells to ensure success leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion. 1998;38:385-91.
24. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin ' s lymphoma. Bone Marrow Transplant. 2004; 33:907-12.
25. Hosing C, Saliba RM, Ahlawat S, Kö r bling M, Kebriaei P, Alousi A, et al. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009; 84:335-7.
26. + cell yield. J Clin Apher. 2011;26: 111-15.
27. Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion. 2004;44:777-84.
28. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foron JM, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin ' s lymphoma. Hematol J. 2000;1:367-73.
29. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861-5.
30. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298-312
31. Tournilhac O, Cazin B, Lepé tre S, Divin é M, Maloum K, Delmer A, et al. Impact of frontline fl udarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-Cell chronic lymphocytic leukemia. Blood. 2004;103:363-5.
32. Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O, et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fl udarabine suggest impaired bone marrow niche and HP mobilization. Leukemia. 2008;22:2131-4.
33. Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-Realted MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47: 488-493.
34. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant. 1998;22:859-69.
35. Stiff PJ. Management strategies for the hard-To-Mobilize patient. Bone Marrow Transplant. 1999;23 (Suppl 2):S29-33.
36. Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, et al. Central and Eastern European Leukemia Group (CELG). Identifi cation of prognostic factors for plerixaforbased hematopoietic stem cell mobilization. Am J Hematol. 2011;86:550-3.
37. Sag ü é s M, Sancho JM, Serrano D, Balsalobre P, Gayoso J, Morgades M, et al. Comparison of two initial mobilizing strategies of peripheral blood stem cells for autologous transplantation in patients with lymphoma and human immunodefi ciency virus infection. Med Clin (Barc). 2011. Epub ahead of print.
38. + peripheral blood progenitor cells in normal donors. Br J Haematol. 2000;109:770-2.
39. Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identifi cation of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion. 2011;51:587-90.
40. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, et al. Predicting PBSC harvest failure using circulating CD34levels: Developing target-Based cutoff points for early intervention. Bone Marrow Transplant. 2011;46: 943-9.